Trulicity Label Update; Canagliflozin Success for CKD; Capsaicin for Weight Loss

— News and commentary from the endocrinology world

by Kristen Monaco, Staff Writer, �鶹��ý July 20, 2018

This article is a collaboration between �鶹��ý and:

The phase III involving canagliflozin (Invokana) -- with around 4,400 patients with type 2 diabetes and kidney disease -- is being stopped early due to positive findings, the maker Janssen announced. Canagliflozin was able to reduce the risk for the composite endpoint: time to dialysis or kidney transplantation, doubling of serum creatinine, and renal or cardiovascular death.

The label for Eli Lilly's GLP-1 agonist was updated this week to include data from the trial showing safety and efficacy in patients also with moderate to severe chronic kidney disease.

The elevated risk for death can persist for up to a decade following a for older adults. "While intervention after the first fracture is critical, we also need to diagnose those at risk of breaking bones before these major health impacts have occurred," said study author Jacqueline Center, MBBS, PhD, of the Garvan Institute of Medical Research in Australia. (Journal of Clinical Endocrinology & Metabolism)

Amgen and UCB, makers of postmenopausal osteoporosis drug romosozumab (Evenity), for FDA approval after their application was 1 year ago. (Pharmaphorum/PM Live)

Capsaicin -- the hot stuff in chili peppers -- showed promise as part of the in a mouse model. The drug improved blood glucose, cholesterol, and weight loss without inflammation. (ScienceDaily)

New were published by the International PCOS Network. "It is now vital to get the key guideline messages out to as broad a range of health professionals and women with PCOS as possible to translate this work into improved health outcomes for affected women," said guideline leaders Jacqueline Boyle, MBBS, and Rhonda Garad, PhD, of Monash University in Australia, in a statement. (Fertility and Sterility)

In similar news, the first international consensus statement for -- a rare endocrine condition related to Albright hereditary osteodystrophy -- was also recently published. (Nature Reviews Endocrinology)

Liver cancer deaths rose 43% since 2000, mainly due to obesity and its handmaidens including diabetes and non-alcoholic steatohepatitis, according to a new CDC report.

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.